Industry News
Aspirin may act on two different pathways to improve survival in colon cancer
Oct 02, 2013
Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer, the 2013 European Cancer Congress (ECC2013) [1] heard. Although previous research has shown that taking low dose aspirin after being diagnosed with colon cancer improves patient outcome, the reasons why this happens remain unknown... Read More
The biggest killer of Hispanic Texans is cancer
Oct 02, 2013
More Hispanic Texans die from cancer than any other cause, according to a new report by the Comparative Effectiveness Research on Cancer in Texas research group. The report documents cancer as the leading cause of death among Hispanic Texans under the age of 76. Only three percent of Hispanic Texans are older than 75. Texas's Hispanic population has more than doubled since 1990... Read More
Anti-cancer drug and radiotherapy may lead to treatment for brain tumor
Oct 02, 2013
Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumours, as well as a potential new biological marker than can predict the tumour's response to treatment... Read More
Radiotherapy dose wasted in compensating for between-treatment tumor growth
Oct 02, 2013
For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer... Read More
Blood test detects cancer metastasis
Oct 02, 2013
Researchers from the University Gbrbrttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer... Read More
Study published in Blood highlights Axl inhibition as a novel therapeutic approach for Acute Myeloid Leukemia
Oct 01, 2013
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma"[1] by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology. The paper reports research directed by Dr... Read More
Erbitux significantly extends survival by 7.5 Months in mCRC RAS wild-type patients when compared with Bevacizumab: New analysis of FIRE-3 AIO study
Oct 01, 2013
Merck Serono, the biopharmaceutical division of Merck, has announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatmen... Read More
Melanoma patients treated with ipilimumab can survive up to 10 years
Oct 01, 2013
Patients with advanced melanoma, who have been treated with the monoclonal antibody, ipilimumab, can survive for up to ten years, according to the largest analysis of overall survival for these patients, presented at the 2013 European Cancer Congress (ECC2013) [1]... Read More
The risk of developing and dying from breast and colon cancer increased by diabetes
Oct 01, 2013
Diabetes is linked to an increased risk of developing cancer, and now researchers have performed a unique meta-analysis that excludes all other causes of death and found that diabetic patients not only have an increased risk of developing breast and colon cancer but an even higher risk of dying from them... Read More
Increased mortality risk for younger patients with metastatic colorectal cancer
Oct 01, 2013
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments. Their disease is more likely to progress and they are at greater risk of death than other age groups, according to new reseach presented to the 2013 European Cancer Congress (ECC2013) [1]... Read More
Previous Page Next Page